You can qualify through any one of these.
Initial Approval — OSA in Adults with Obesity (No Concurrent T2DM)
All of:
- Patient is within the FDA-labeled age range (adults)
- Diagnosis of moderate to severe OSA confirmed by sleep study within the past 12 months with AHI >= 15 events/hour
- Diagnosis of obesity with documented BMI >= 30 kg/m² within the past 3 months (date and BMI result stated on request)
- Patient has been prescribed or counseled on use of CPAP as a potential therapy
- Patient has received counseling on chronic weight management (increased physical activity and reduced calorie diet) and will continue ongoing counseling during treatment
- Patient is not receiving Zepbound in combination with other tirzepatide-containing products or any other GIP/GLP-1 class agents
Initial Approval — OSA in Adults with Obesity and Concurrent Type II Diabetes
All of:
- Patient is within the FDA-labeled age range (adults)
- Diagnosis of moderate to severe OSA confirmed by sleep study within the past 12 months with AHI >= 15 events/hour
- Diagnosis of obesity with documented BMI >= 30 kg/m² within the past 3 months (date and BMI result stated on request)
- Patient has been prescribed or counseled on use of CPAP as a potential therapy
- Patient has received counseling on chronic weight management (increased physical activity and reduced calorie diet) and will continue ongoing counseling during treatment
- Patient has concurrent diagnosis of Type II Diabetes Mellitus and has been trialed on a preferred GLP-1 (indicated for Type II DM) compliantly for three months with treatment failure
- Patient is not receiving Zepbound in combination with other tirzepatide-containing products or any other GIP/GLP-1 class agents